Germany · Delayed Price · Currency is EUR Evonik Industries AG Earnings Call Transcripts
Fiscal Year 2026
-
Resilience, sustainability, and innovation are integrated to address global challenges and drive growth. Key initiatives include advanced biosolutions, green hydrogen, and circular economy solutions, supported by a restructured R&D organization and international hubs.
-
The meeting addressed leadership changes, a challenging financial year, and a shift to a performance-based dividend policy. Strategic initiatives focus on innovation, cost discipline, and green transformation, with continued investment in growth areas.
-
Q1 2026 adjusted EBITDA exceeded expectations at EUR 475 million, driven by strong Advanced Technologies and pre-buying effects, while free cash flow remained robust. Q2 EBITDA is guided to at least EUR 550 million, but risks from inflation and supply chain disruptions persist.
Fiscal Year 2025
-
Delivered solid 2025 results with EUR 1.9 billion adjusted EBITDA and strong cash flow. 2026 guidance targets stable earnings amid persistent weak demand, cost savings, and a new flexible dividend policy. Regulatory and market changes, especially in methionine and Oxeno, will shape performance.
-
Q3 results were weak, leading to a revised full-year EBITDA guidance of EUR 1.9 billion, but confidence remains in meeting targets due to strong healthcare and Animal Nutrition recovery. Structural cost savings, new plant ramp-ups, and the SYNEQT carve-out are expected to support future performance despite ongoing market challenges.
-
Q2 results were resilient despite macro headwinds, with core segments stable and cost savings underway. Full-year guidance is maintained at the lower end, but achieving it depends on macro improvement and strict cost controls.
-
A new group structure with two segments and a focus on innovation, operational excellence, and regional balance underpins the strategy to deliver €1 billion additional EBITDA and 11% ROCE by 2027. Capital allocation prioritizes organic growth, dividends, and debt reduction, with share buybacks considered post-divestments.
-
Q1 2025 saw EBITDA and free cash flow rise, with over 50% year-over-year EBITDA growth and record sales. Full-year guidance is confirmed, supported by strong specialty additives and nutrition and care segments, while risks from macroeconomic and trade factors persist.
Fiscal Year 2024
-
Delivered 25% EBITDA growth and strong free cash flow in 2024, with continued earnings growth expected in 2025 driven by cost savings, innovation, and robust segment performance. Market sentiment has improved, and a new segment structure will enhance business steering.
-
Q3 2024 saw improved margins, strong free cash flow, and sector-leading earnings growth, driven by cost savings, portfolio realignment, and innovation focus. Specialty Additives and Silica outperformed, while Healthcare and Performance Materials faced challenges. Guidance and free cash flow targets were reaffirmed.
-
Two new flexible epoxy curing agents, Ancamide 2853 and 2865, address market needs for high elongation, toughness, and eco-friendly profiles, with adjustable performance and fast cure times. Both are nonylphenol-free, contain bio content, and are available globally except Europe.
-
Q2 2024 saw sector-leading earnings growth, strong free cash flow, and an upgraded EBITDA outlook. Focus remains on internal optimization, targeted investments, and disciplined capital allocation, with no M&A planned through 2025. Guidance reflects confidence despite macro uncertainties.
-
The AGM highlighted a challenging 2023 with declining sales and profits, but strong free cash flow enabled a stable dividend. Strategic restructuring, divestments, and sustainability initiatives were advanced, while risks from geopolitical crises and policy uncertainty remain significant.